SG10202102061SA - Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof - Google Patents

Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof

Info

Publication number
SG10202102061SA
SG10202102061SA SG10202102061SA SG10202102061SA SG10202102061SA SG 10202102061S A SG10202102061S A SG 10202102061SA SG 10202102061S A SG10202102061S A SG 10202102061SA SG 10202102061S A SG10202102061S A SG 10202102061SA SG 10202102061S A SG10202102061S A SG 10202102061SA
Authority
SG
Singapore
Prior art keywords
channelopsin
mutations
variants
identification
methods
Prior art date
Application number
SG10202102061SA
Other languages
English (en)
Inventor
Zhuo-Hua Pan
Original Assignee
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wayne State filed Critical Univ Wayne State
Publication of SG10202102061SA publication Critical patent/SG10202102061SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10202102061SA 2016-08-29 2017-08-29 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof SG10202102061SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662380871P 2016-08-29 2016-08-29

Publications (1)

Publication Number Publication Date
SG10202102061SA true SG10202102061SA (en) 2021-04-29

Family

ID=59859616

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202102061SA SG10202102061SA (en) 2016-08-29 2017-08-29 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
SG11201901697QA SG11201901697QA (en) 2016-08-29 2017-08-29 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201901697QA SG11201901697QA (en) 2016-08-29 2017-08-29 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof

Country Status (15)

Country Link
US (3) US11041004B2 (https=)
EP (1) EP3504227A1 (https=)
JP (1) JP7116884B2 (https=)
KR (3) KR102609571B1 (https=)
CN (2) CN110023327B (https=)
AU (4) AU2017319306B2 (https=)
BR (1) BR112019003950A2 (https=)
CA (1) CA3034887A1 (https=)
IL (2) IL265010B2 (https=)
MX (1) MX2019002321A (https=)
MY (1) MY197491A (https=)
NZ (1) NZ751983A (https=)
RU (1) RU2019109021A (https=)
SG (2) SG10202102061SA (https=)
WO (1) WO2018044912A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3504227A1 (en) 2016-08-29 2019-07-03 Wayne State University Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
CN113173984B (zh) 2021-04-12 2022-08-30 中眸医疗科技(武汉)有限公司 一种新型光敏感通道蛋白vr1.0在制备视网膜感光细胞退行性疾病药物中的应用
MX2024007770A (es) * 2021-12-20 2024-07-01 Genans Biotechnology Co Ltd Restauracion visual optogenetica utilizando neuropsina acoplada a gq sensible a la luz (opsin 5).
EP4665750A1 (en) 2023-02-17 2025-12-24 Ray Therapeutics, Inc. Gene therapy compositions and methods for treating diseases of the retina
WO2025137649A1 (en) * 2023-12-22 2025-06-26 Wayne State University Method of enhancing viral mediated gene delivery

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
EP1919497B1 (en) 2005-07-22 2020-02-12 The Board of Trustees of the Leland Stanford Junior University Light-activated cation channel and uses thereof
CN101484005A (zh) 2006-05-04 2009-07-15 韦恩州立大学 通过向体内递送视紫红质核酸恢复视觉响应
KR100922422B1 (ko) 2006-06-27 2009-10-16 가부시키가이샤 어드밴테스트 반도체 시험 장치 및 반도체 메모리의 시험 방법
WO2011140279A1 (en) 2010-05-04 2011-11-10 Wayne State University Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
KR101945962B1 (ko) 2010-09-08 2019-02-08 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 돌연변이 채널로돕신 2
CN105755044A (zh) 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
WO2013071231A1 (en) * 2011-11-12 2013-05-16 Massachusetts Institute Of Technology Channelrhodopsins for optical control of cells
CA2866405A1 (en) * 2012-03-05 2013-09-12 Wayne State University Identification of channelopsin-2 (chop2) mutations and methods of use
EP2968476B1 (en) * 2013-03-14 2021-05-05 Wayne State University A plasmin for use in enhancing delivery of therapeutic compounds to the eyes or for improving vision
EP3102290A1 (en) * 2014-02-07 2016-12-14 Massachusetts Institute Of Technology Blue light-activated ion channel molecules and uses thereof
EP4678754A3 (en) 2014-03-11 2026-04-08 Wayne State University A modified mglur6 promoter and methods of use
WO2015161308A1 (en) 2014-04-18 2015-10-22 Massachusetts Institute Of Technology Mutant channelrhodopsins with altered ion selectivity
WO2016179038A1 (en) 2015-05-01 2016-11-10 Spark Therapeutics, Inc. ADENO-ASSOCIATED VIRUS-MEDIATED CRISPR-Cas9 TREATMENT OF OCULAR DISEASE
LT3436051T (lt) 2016-03-31 2021-11-25 Spark Therapeutics, Inc. Kolonėlėmis pagrįstas visiškai keičiamo masto raav gavimo būdas
WO2017210664A1 (en) 2016-06-03 2017-12-07 Massachusetts Institute Of Technology Somatic opsins for single cell resolution optogenetics
AU2017302013B2 (en) 2016-07-29 2022-05-26 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
EP3504227A1 (en) 2016-08-29 2019-07-03 Wayne State University Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof

Also Published As

Publication number Publication date
IL265010B1 (en) 2024-02-01
SG11201901697QA (en) 2019-03-28
JP7116884B2 (ja) 2022-08-12
US11041004B2 (en) 2021-06-22
RU2019109021A (ru) 2020-09-29
WO2018044912A1 (en) 2018-03-08
KR102609571B9 (ko) 2025-11-20
IL310142A (en) 2024-03-01
EP3504227A1 (en) 2019-07-03
JP2019528781A (ja) 2019-10-17
AU2024200016B2 (en) 2025-07-17
AU2024200016A1 (en) 2024-01-25
BR112019003950A2 (pt) 2019-06-25
CA3034887A1 (en) 2018-03-08
KR20250159068A (ko) 2025-11-07
US20250163111A1 (en) 2025-05-22
US12234267B2 (en) 2025-02-25
KR20230169427A (ko) 2023-12-15
NZ751983A (en) 2025-11-28
AU2022201291B2 (en) 2023-10-05
MY197491A (en) 2023-06-19
IL265010A (https=) 2019-04-30
AU2024200016B9 (en) 2025-08-07
KR20190075906A (ko) 2019-07-01
KR102609571B1 (ko) 2023-12-01
AU2017319306B2 (en) 2021-12-02
AU2022201291A1 (en) 2022-03-17
CN119979612A (zh) 2025-05-13
MX2019002321A (es) 2019-10-21
US20220089660A1 (en) 2022-03-24
US20190241628A1 (en) 2019-08-08
RU2019109021A3 (https=) 2021-02-02
AU2025248765A1 (en) 2025-10-30
AU2017319306A1 (en) 2019-04-11
IL265010B2 (en) 2024-06-01
KR102877327B1 (ko) 2025-10-27
CN110023327B (zh) 2024-02-27
CN110023327A (zh) 2019-07-16

Similar Documents

Publication Publication Date Title
HUS2400028I1 (hu) PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
IL292094A (en) Neoantigens and methods for using them
IL272364A (en) Identifying nuisances and defects of interest in defects detected on a wafer
IL293715B1 (en) Automatic detection and new positioning of micro-objects in microfluidic devices
IL266093A (en) Oxysterols and methods of using them
IL266092A (en) Oxysterols and methods of using them
ZA202003695B (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
IL256179A (en) lag-3 binding molecules and methods of using them
SI3258951T1 (sl) Anti-pvrig protitelesa in metode uporabe
PT3436022T (pt) Oxisteróis e métodos de utilização dos mesmos
GB2549779B (en) Security elements and methods of manufacture thereof
SG10202102061SA (en) Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
ZA201902325B (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
GB2538491B (en) Security documents and methods of manufacture thereof
PT3258960T (pt) Proteínas imunoprotetoras de leptospira e métodos de identificação e sua utilização
GB201521668D0 (en) Optical sensor and methods of use and fabrication
PT3468603T (pt) Variantes do fec-gm e métodos de utilização
GB201603405D0 (en) Breath identification and matching
HK40011220A (en) Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
GB201619731D0 (en) Security device components and methods of manufacture thereof
PT3512849T (pt) 1-arilnaftiridina-3-carboxamidas 7-substituídas e sua utilização
GB201514412D0 (en) Determination of influenza and HEV susceptibility